Satoshi Shoji, MD, PhD
@SS_cardiolCardiology Research Fellow @ DCRI, Outcome Researcher of Heart Failure and Coronary Intervnetion, Father of 2. Tweets are my own.
The win ratio in cardiology trials: lessons learnt, new developments, and wise future use. Read more in #EHJ. doi.org/10.1093/eurhea… #statistical #clinicaltrial #cardiotwitter @ESC_Journals @escardio
Check out the latest #DontMissABeat for nuggets of wisdom from @tmodarressi who takes a deep dive into practical tips for improving prescription, adherence, and access to new #cardiometabolic therapies w/ @SJGreene_md & @mvaduganathan hcplive.com/view/dont-miss… #HeartFailure
今週読んだ論文で秀逸の1本だったJACCのSGLT2阻害薬の性器尿路感染症に関するレビュー。とてもまとまっててよかったので関心のある方是非。 sciencedirect.com/science/articl…
Apply now to be Editor in Chief of the new 💜JCF Intersections💜 Amazing opportunity to build a world-class team, innovate academic publishing & have an incredible time along the way! Feel free to reach out with questions - Let's do this! hfsa.org/jcf-intersecti… @dranulala @HFSA
🚨 JCF & @HFSA are proud to announce a NEW #OpenAccess journal: JCF-INTERSECTIONS, in partnership w/ @ElsevierConnect! JCF-I will focus on the intersection of Heart #FunctionNotFailure & other CV disciplines, emphasizing high-quality science & #DEI. 🔗 hfsa.org/jcf-intersecti…
🚨 JCF & @HFSA are proud to announce a NEW #OpenAccess journal: JCF-INTERSECTIONS, in partnership w/ @ElsevierConnect! JCF-I will focus on the intersection of Heart #FunctionNotFailure & other CV disciplines, emphasizing high-quality science & #DEI. 🔗 hfsa.org/jcf-intersecti…
Thrilled to announce we’ve signed on to help lead JCF for 3 more yrs! No better way to do this than to partner w @dranulala as Co-Editor-in-Chief Thanks to #JCFfamily, @HFSA & broader HF community for trusting us to serve in these roles Let’s constructively disrupt together!
In a new interview with @CardioBusiness, #JACC editor-in-chief Dr. Harlan Krumholz shared his vision for the future of #JACCJournals. "We need to give people information in the way they like to consume it," @hmkyale said. Find the full story here: bit.ly/3zsA7DE
Awesome outdoor journal club on FINEARTS study with @DukeCardFellows @DukeCardiology @FudimMarat @robmentz @DCRINews
Original Article: Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease (EPIC-CAD) nej.md/3Z1D1d3 Editorial: Atrial Fibrillation and Stable Coronary Artery Disease nej.md/3T5MV9G #ESCardio | @escardio
Great to see our fantastic JACC Asia-Pacific Japan Team Members in person at the ESC@London🇬🇧 @sk2798 @SS_cardiol #Takeshi_Kitai @JACCJournals #ESCCongress2024
Excited to share that our review paper, "Embracing an Era of Targeted Combination Therapy for Heart Failure with Preserved Ejection Fraction," is now published in #HREV! Special thanks to my mentors @SJGreene_md and @robmentz Check it out! link.springer.com/article/10.100… @KPHeartDoc
It is fitting to have this primer on upfront combination therapy in HFpEF from @SJGreene_md and @robmentz out in #HREV (link.springer.com/article/10.100…) ahead of FINEARTS presentation at ESC. Growing therapeutic options! @mvaduganathan @AndrewJSauer @MkosiborodMD
In a multicenter cohort of chronic HFrEF patients, only 50% of patients were on optimal therapy as defined by the OMT score that is based on receipt of beta-blocker, ACEI/ARB/ARNI, and MRA at appropriate target doses. Read more: bit.ly/3WUFwfH #JACCHF
Across a large cohort of chronic ambulatory HFrEF, better OMT scores associated with lower risk of all-cause and cardiovascular death Optimal Medical Therapy and Outcomes Among Patients With Chronic Heart... sciencedirect.com/science/articl… @_adevore @texhern @JavedButler1 @SJGreene_md
Viewpoint from @ProfSNicholls, @lamcardio, and Adam Nelson discusses the potential challenges to the operational conduct of clinical trials in the Asia-Pacific region, where there is a high rate of cardiovascular disease. ja.ma/4dw8iZM
🔴 Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, & omecamtiv mecarbil in the therapeutic armamentarium #Cardioed #Cardiology #CardioTwitter
“I envision @JACCJournals, with all its strengths, as a transformative platform for building community, elevating strong science, influencing clinical practice, supporting career development, and improving patient outcomes.” My (open-access) Editor’s page. jacc.org/doi/epdf/10.10…
📣【重要なお知らせ】 🇯🇵日本の先生方へ 🆕いよいよ2024年7月よりJACC新体制の幕開けです！ 詳しくは編集長のHarlan Krumholz先生のオープンアクセス記事をご参照ください：jacc.org/doi/10.1016/j.…
“I envision @JACCJournals, with all its strengths, as a transformative platform for building community, elevating strong science, influencing clinical practice, supporting career development, and improving patient outcomes.” My (open-access) Editor’s page. jacc.org/doi/epdf/10.10…
What is a cost-effective GDMT strategy for HFmrEF/HFpEF? We built a model w/ clinical trial data (TOPCAT, PARAGON-HF, EMPEROR/DELIVER) and simulated outcomes w/ regimens of MRA/SGLT2i/ARNi. Best 💊 combo? MRA + SGLT2i ARNi ⬇️ value at current 💵 Treat HF with urgency!
Important work led by @senthil_selv with fantastic coauthor team @SvatiShah @scottdsolomon @DukeHeartCenter @DukeHealth
Among self-reported Black individuals, male & female V142I transthyretin variant carriers faced similar & substantial risk for HF hospitalization, predominantly with reduced ejection fraction, & death, with steep age-dependent penetrance. ja.ma/4anxP5u #HeartFailure2024
Only fitting during #Sarcoidosis Awareness Month our first presentation on rounds today is a cardiac #sarcoidosis patient. And that #Osler teaching included the hot-off-the-press @AHAScience Guidelines Statement on Sarcoidosis Diagnosis and Treatment by none other than…
United States Trends
- 1. GOTY 31,5 B posts
- 2. Balatro 17,5 B posts
- 3. Mika 94,5 B posts
- 4. #Strobepopcat N/A
- 5. #TheGameAwards 38,8 B posts
- 6. Elden Ring 26,2 B posts
- 7. #AskShadow N/A
- 8. Metaphor 24,4 B posts
- 9. Shadow of the Erdtree 9.507 posts
- 10. Ichiro 4.098 posts
- 11. Morning Joe 76,4 B posts
- 12. Stellar Blade 10,3 B posts
- 13. Game of the Year 35,1 B posts
- 14. Astro Bot 3.374 posts
- 15. SOTE 3.407 posts
- 16. Silent Hill 2 12,8 B posts
- 17. $CUTO 9.856 posts
- 18. Wukong 16,9 B posts
- 19. Geoff 8.745 posts
- 20. Helldivers 2 4.330 posts
Something went wrong.
Something went wrong.